Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00891059 · ClinicalTrials.gov registry record

The Role Of Cognitive Impairment In The Use Of The Diskus Inhaler

A clinical trial of Cognitive Impairment, sponsored by Synergy Health Solutions.

Completed
Registry status
40
Enrollment target
2
Study locations

NCT00891059: Completed study of Cognitive Impairment, sponsored by Synergy Health Solutions.

NCT00891059 is a study of Cognitive Impairment that has completed, run by Synergy Health Solutions. The registered enrollment target is 40 participants, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00891059, a study of Cognitive Impairment, has completed, sponsored by Synergy Health Solutions.

COMPLETED
Registry status
40 participants
Enrollment target
2
Study locations

Study Summary

The Diskus Inhaler is administered by a nurse or medical technician in the Nursing Home (NH) setting. The administration of the medication from the Diskus Inhaler includes 4 steps: open, click, inhale, close. The only step that the resident must do is the "inhale" step, which includes holding one's breath for 10 seconds after the inhalation. The investigators propose that properly trained and motivated nurses and medical technicians can successfully administer medication using the Advair Diskus to almost any mildly to moderately cognitively impaired resident who can follow the instruction- "inhale" and hold your breath for 10 seconds". The objective is to show that mild to moderate cognitive impairment should not be a barrier to the use of Diskus Inhaler. There will only be 1 consent visit and 1 evaluation visit per subject.

Conditions Studied

Study Locations (2)

Florida

  • Brooksville Health Care Center - Brooksville

Ohio

  • Bethany Village - Centerville

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2009-05
Est. Completion 2009-07
Synergy Health Solutions

1 total trials

What the finished NCT00891059 record still lists

NCT00891059 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Cognitive Impairment appearing as the primary indexed condition, and to 0 interventions.

NCT00891059 reports a single indexed study location in Florida, Ohio.

Frequently Asked Questions

What is clinical trial NCT00891059 about?

NCT00891059 is a clinical study titled "The Role Of Cognitive Impairment In The Use Of The Diskus Inhaler". The Diskus Inhaler is administered by a nurse or medical technician in the Nursing Home (NH) setting. The administration of the medication from the Diskus Inhaler includes 4 steps: open, click, inhale, close. The only step that the resident must do is the "inhale" step, which includes holding one's ...

What is the current status of trial NCT00891059?

This trial is currently completed. The enrollment target is 40 participants. The study started on 2009-05. Estimated completion is 2009-07.

What conditions does trial NCT00891059 study?

This clinical trial studies the following conditions: Cognitive Impairment.

Who is sponsoring clinical trial NCT00891059?

This trial is sponsored by Synergy Health Solutions, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00891059 being conducted?

This trial has 2 study locations across Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cognitive Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00891059's enrollment target sits among peer trials

40 78th of 105 higher than 23 of 105 other Cognitive Impairment trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00891059, the US trial registry maintained by the National Library of Medicine. NCT00891059 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.